Literature DB >> 7437270

Clinical pharmacokinetics of salicylates: a re-assessment.

G Levy.   

Abstract

1 Aspirin is partly hydrolyzed to salicylic acid during absorption. Absorbed aspirin is rapidly hydrolyzed systemically. Salicylic acid elimination kinetics are dependent on drug concentration due to the limited capacity of two major biotransformation pathways: formation of salicyluric acid and of salicylphenolic glucuronide. 2 The time courses of the various pharmacological effects of single doses of aspirin are not directly coincident with the plasma concentrations of either aspirin or salicylic acid but there is reasonably good evidence that the pharmacological effects are related to the concentration of aspirin, salicylic acid, or both. 3 Steady-state plasma salicylate concentrations increase more than proportionally with increasing daily dose; the time required to reach steady state increases with increasing daily dose. Dosage intervals of 8 or even 12 h are usually sufficient to maintain plasma salicylate concentrations in the anti-inflammatory concentration range. Monitoring of plasma salicylate concentrations in this range is facilitated by the relatively small drug concentration fluctuations during a dosing interval at steady-state. 4 Limited data suggest that the pharmacological activity of salicylate is produced by free (unbound) drug. As the plasma protein binding of salicylic acid is concentration-dependent and subject to pronounced interindividual differences, it is preferable, at least in principle, to monitor free rather than total concentrations of salicylate in plasma. Although salicylate concentration in saliva reflects the free rather than total salicylate concentration in plasma or serum, use of saliva for indirect monitoring of plasma salicylate concentrations seems to be impractical for technical reasons.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7437270      PMCID: PMC1430201          DOI: 10.1111/j.1365-2125.1980.tb01811.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  31 in total

1.  Limited capacity for salicyl phenolic glucuronide formation and its effect on the kinetics of salicylate elimination in man.

Authors:  G Levy; T Tsuchiya; L P Amsel
Journal:  Clin Pharmacol Ther       Date:  1972 Mar-Apr       Impact factor: 6.875

2.  The clinical dose response to aspirin.

Authors:  J Parkhouse; M Rees-Lewis; M Skolinik; H Peters
Journal:  Br J Anaesth       Date:  1968-06       Impact factor: 9.166

3.  Absorption kinetics of aspirin in man following oral administration of an aqueous solution.

Authors:  M Rowland; S Riegelman; P A Harris; S D Sholkoff
Journal:  J Pharm Sci       Date:  1972-03       Impact factor: 3.534

4.  Salicylate accumulation kinetics in man.

Authors:  G Levy; T Tsuchiya
Journal:  N Engl J Med       Date:  1972-08-31       Impact factor: 91.245

5.  A clinical evaluation of a sustained-release aspirin.

Authors:  L J Cass; W S Frederik
Journal:  Curr Ther Res Clin Exp       Date:  1965-11

6.  Clinical comparison of a sustained- and a regular-release aspirin.

Authors:  L J Cass; W S Frederik
Journal:  Curr Ther Res Clin Exp       Date:  1965-11

7.  Influence of the route of administration on the area under the plasma concentration-time curve.

Authors:  P A Harris; S Riegelman
Journal:  J Pharm Sci       Date:  1969-01       Impact factor: 3.534

8.  Measuring measurin: problems of oral prolonged-action medications.

Authors:  L E Hollister
Journal:  Clin Pharmacol Ther       Date:  1972 Jan-Feb       Impact factor: 6.875

9.  Kinetics of pharmacologic effects.

Authors:  G Levy
Journal:  Clin Pharmacol Ther       Date:  1966 May-Jun       Impact factor: 6.875

10.  Aspirin, absorption rate and analgesic effect.

Authors:  G Levy
Journal:  Anesth Analg       Date:  1965 Nov-Dec       Impact factor: 5.108

View more
  22 in total

1.  [Not Available].

Authors:  E Hackenthal
Journal:  Schmerz       Date:  1990-09       Impact factor: 1.107

Review 2.  Drug interactions involving aspirin (acetylsalicylic acid) and salicylic acid.

Authors:  J O Miners
Journal:  Clin Pharmacokinet       Date:  1989-11       Impact factor: 6.447

3.  Reduction in gastric mucosal hemorrhage and ulceration with chronic high-level dosing of enteric-coated aspirin granules two and four times a day.

Authors:  F L Lanza; M F Rack; G S Wagner; T K Balm
Journal:  Dig Dis Sci       Date:  1985-06       Impact factor: 3.199

Review 4.  Antirheumatic drug concentrations in human synovial fluid and synovial tissue. Observations on extravascular pharmacokinetics.

Authors:  W J Wallis; P A Simkin
Journal:  Clin Pharmacokinet       Date:  1983 Nov-Dec       Impact factor: 6.447

Review 5.  Clinical significance of esterases in man.

Authors:  F M Williams
Journal:  Clin Pharmacokinet       Date:  1985 Sep-Oct       Impact factor: 6.447

Review 6.  Nonsteroidal anti-inflammatory drugs in perisurgical pain management. Mechanisms of action and rationale for optimum use.

Authors:  J Cashman; G McAnulty
Journal:  Drugs       Date:  1995-01       Impact factor: 9.546

7.  Model representation of salicylate pharmacokinetics using unbound plasma salicylate concentrations and metabolite urinary excretion rates following a single oral dose.

Authors:  J Shen; S Wanwimolruk; R D Purves; E G McQueen; M S Roberts
Journal:  J Pharmacokinet Biopharm       Date:  1991-10

Review 8.  The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings.

Authors:  Garry G Graham; Michael J Davies; Richard O Day; Anthoulla Mohamudally; Kieran F Scott
Journal:  Inflammopharmacology       Date:  2013-05-30       Impact factor: 4.473

Review 9.  Aspirin and related derivatives of salicylic acid.

Authors:  S P Clissold
Journal:  Drugs       Date:  1986       Impact factor: 9.546

Review 10.  Clinical pharmacokinetics of drugs used in juvenile arthritis.

Authors:  K J Skeith; F Jamali
Journal:  Clin Pharmacokinet       Date:  1991-08       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.